Top

 

References

  1. Neale BM, et al. Meta-analysis of genome-wide association studies of attention deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2010; 49: 884–897.
  2. Volkow ND, et al. evaluating dopamine reward pathway in ADHD: clinical implications. JAMA 2009; 302: 1084–1091.
  3. Valera EM, et al. Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol Psychiatry 2007; 61: 1361–1369.
  4. Dickstein SG, et al. The neural correlates of attention deficit hyperactivity disorder: an ALE meta-analysis. J Child Psychol Psychiatry 2006; 147: 1051–1062.
  5. Ivanov I, et al. Morphological abnormalities of the thalamus in youths with attention deficit hyperactivity disorder. Am J Psychiatry 2010; 167: 397–408.
  6. Farone SV, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57: 1313–1323.
  7. National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: Diagnosis and management of ADHD in children, young people and adults. Clinical guideline 72. Available at: http://guidance.nice.org.uk/cg72 [accessed April 2015].
  8. National Institute for Health and Care Excellence. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Review of technology appraisal 98. Available at: www.nice.org.uk/TA098 [accessed April 2015].
  9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Fifth edition. 2013.
  10. Scottish Intercollegiate Guidelines Network. Management of attention deficit and hyperkinetic disorders in children and young people: a national clinical guideline. Guideline 112; October 2009. Available at: www.sign.ac.uk [accessed April 2015].
  11. Taylor E, et al. European clinical guidelines for hyperkinetic disorder – first upgrade. Eur Child Adolesc Psychiatry 2004; 13 Suppl 1: 117–130.
  12. Chronis AM, et al. Evidence-based psychosocial treatments for children and adolescents with attention-deficitlhyperactivity disorder. Clin Psychol Rev 2006; 26: 486–502.
  13. Ritalin Summary of Product Characteristics. Available at: www.medicines.org.uk [accessed January 2015].
  14. Concerta XL Summary of Product Characteristics. Available at: www.medicines.org.uk [accessed January 2015].
  15. Equasym XL Summary of Product Characteristics. Available at: www.medicines.org.uk [accessed January 2015].
  16. Dexamfetamine Summary of Product Characteristics. Available at: www.medicines.org.uk [accessed January 2015].
  17. Elvanse Summary of Product Characteristics. Available at: www.medicines.org.uk [accessed January 2015].
  18. Strattera Summary of Product Characteristics. Available at: www.medicines.org.uk [accessed January 2015].
  19. Nigg JT, et al. Meta-analysis of attention-deficit/hyperactivity disorder or attention-deficit/hyperactivity disorder symptoms, restriction diet, and synthetic food color additives. J Am Acad Child Adolesc Psychiatry 2012; 51: 86–97.
 

Top

ADHD-Mobile
Resource

Resources

Visit our resource centre for useful information and helpful activities for parents, teachers and teenagers living with ADHD.

 

Top

home_paralax_logo_320